HemaQuest Pharmaceuticals Obtains $13,000,000 Series B Financing
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=bdba02ff-1aa0-4eb6-b5be-8275108f1f5e&Preview=1 - Date
3/12/2012 - Company Name
HemaQuest Pharmaceuticals - Mailing Address
11995 El Camino Real San Diego, CA 92130 - Company Description
HemaQuest is a company developing proprietary small molecule therapeutics to treat serious blood disorders. - Website
http://www.hemaquest.com - Transaction Type
Venture Equity - Transaction Amount
$13,000,000 - Transaction Round
Series B - Proceeds Purposes
Proceeds from the financing will be used to fund a randomized, double-blind, placebo-controlled Phase 2b clinical study evaluating lead product candidate HQK-1001 in patients with sickle cell disease. The Company believes this financing, combined with existing cash balances, will be sufficient to allow completion of the Phase 2b trial and to fund operations through early 2014. - M&A Terms
- Venture Investor
Aberdare Ventures - Venture Investor
De Novo Ventures - Venture Investor
Forward Ventures - Venture Investor
Latterell Venture Partners - Venture Investor
Lilly Ventures
